NCCN Guidelines® Insights: Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines Guidelines
| Authors: | Wierda, W. G.; Brown, J.; Abramson, J. S.; Awan, F.; Bilgrami, S. F.; Bociek, G.; Brander, D.; Chanan-Khan, A. A.; Coutre, S. E.; Davis, R. S.; Eradat, H.; Fletcher, C. D.; Gaballa, S.; Ghobadi, A.; Saad Hamid, M.; Hernandez-Ilizaliturri, F.; Hill, B.; Kaesberg, P.; Kamdar, M.; Kaplan, L. D.; Khan, N.; Kipps, T. J.; Ma, S.; Mato, A.; Mosse, C.; Schuster, S.; Siddiqi, T.; Stephens, D. M.; Ujjani, C.; Wagner-Johnston, N.; Woyach, J. A.; Ye, J. C.; Dwyer, M. A.; Sundar, H. |
| Title: | NCCN Guidelines® Insights: Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines |
| Abstract: | The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease. © 2022 Harborside Press. All rights reserved. |
| Keywords: | antineoplastic agents; antineoplastic agent; protein bcl 2; b cell lymphoma; lymphoma, b-cell; minimal residual disease; neoplasm, residual; chronic lymphatic leukemia; proto-oncogene proteins c-bcl-2; leukemia, lymphocytic, chronic, b-cell; humans; human |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 20 |
| Issue: | 6 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2022-06-01 |
| Start Page: | 622 |
| End Page: | 634 |
| Language: | English |
| DOI: | 10.6004/jnccn.2022.0031 |
| PUBMED: | 35714675 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 August 2022 -- Source: Scopus |
